GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders.GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases.The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 26, 2020 | Seed | Fr2M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Gliaven | — | Seed |
ACE & Company | — | Seed |